Background: Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma showing strong CD20 expression. The role of rituximab in treating NLPHL still needs clarification. Methods: We retrospectively reviewed the outcome of 23 patients with NLPHL treated with rituximab alone or in combination with chemotherapy and/or radiotherapy as part of their first- or second-line treatment. Results: The median follow-up of the whole group was 67 months, and all patients remained alive. Twenty-two patients achieved complete remission after rituximab-based therapy, and one of them relapsed 32 months after treatment. One patient treated with rituximab alone achieved partial remission and progressed 22 months after treatment. Conclusion: The prognosis of NLPHL is excellent.Rituximab combined with chemotherapy and/or radiotherapy appears to prevent disease progression/relapse.

Journal Section:
Editor's choice
Keywords:
Chemotherapy, Hodgkinߣs lymphoma, Nodular lymphocyte-predominant Hodgkinߣs lymphoma, Rituximab
1.
Nogová L, Reineke T, Brillant C, Sieniawski M, Rüdiger T, Josting A, Bredenfeld H, Skripnitchenko R, Müller RP, Müller-Hermelink HK, Diehl V, Engert A; German Hodgkin Study Group: Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008;26:434-439.
[PubMed]
https://doi.org/10.1200/JCO.2007.11.8869
2.
Nogová L, Reineke T, Eich HT, Josting A, Müller-Hermelink HK, Wingbermühle K, Brillant C, Gossmann A, Oertel J, Bollen MV, Müller RP, Diehl V, Engert A: Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 2005;16:1683-1687.
[PubMed]
https://doi.org/10.1093/annonc/mdi323
3.
Chen RC, Chin MS, Ng AK, Feng Y, Neuberg D, Silver B, Pinkus GS, Stevenson MA, Mauch PM: Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol 2010;28:136-141.
[PubMed]
https://doi.org/10.1200/JCO.2009.24.0945
4.
Eichenauer DA, Engert A, André M, Federico M, Illidge T, Hutchings M, Ladetto M; ESMO Guidelines Working Group: Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(suppl 3):iii70-iii75.
[PubMed]
https://doi.org/10.1093/annonc/mdu181
5.
Canellos GP, Mauch P: What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma? J Clin Oncol 2010;28:e8.
[PubMed]
https://doi.org/10.1200/JCO.2009.26.3293
6.
Fanale MA, Lai CM, McLaughlin P, Romaguera J, Fayad L, Hagemeister F, Samaniego F, Rodriguez MA, Neelapu SS, Shah JJ, Kwak L, Dong W, Reed V, Dabaja BS, Popat U, Younes A: Outcomes of nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP (abstract). Blood (ASH Annual Meeting Abstracts) 2010;116:2812.
7.
Xing KH, Connors JM, Lai A, Al-Mansour M, Sehn LH, Villa D, Klasa R, Shenkier T, Gascoyne RD, Skinnider B, Savage KJ: Advanced stage nodular lymphocyte predominant Hodgkin lymphoma compared to classical Hodgkin lymphoma: a matched pair outcome analysis. Blood 2014;123:3567-3573.
[PubMed]
https://doi.org/10.1182/blood-2013-12-541078
8.
Al-Mansour M, Connors JM, Gascoyne RD, Skinnider B, Savage KJ: Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol 2010;28:793-799.
[PubMed]
https://doi.org/10.1200/JCO.2009.24.9516
9.
Biasoli I, Stamatoullas A, Meignin V, Delmer A, Reman O, Morschhauser F, Coiffier B, Bosly A, Diviné M, Brice P: Nodular, lymphocyte-predominant Hodgkin lymphoma. Cancer 2010;116:631-639.
[PubMed]
https://doi.org/10.1002/cncr.24819
10.
Hartmann S, Eichenauer DA, Plütschow A, Mottok A, Bob R, Koch K, Bernd HW, Cogliatti S, Hummel M, Feller AC, Ott G, Möller P, Rosenwald A, Stein H, Hansmann ML, Engert A, Klapper W: The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 2013;122:4246-4252.
[PubMed]
https://doi.org/10.1182/blood-2013-07-515825
11.
Eichenauer DA, Fuchs M, Pluetschow A, Klimm B, Halbsguth T, Böll B, von Tresckow B, Nogová L, Borchmann P, Engert A: Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2011;118:4363-4365.
[PubMed]
https://doi.org/10.1182/blood-2011-06-361055
12.
Advani RH, Horning SJ, Hoppe RT, Daadi S, Allen J, Natkunam Y, Bartlett NL: Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol 2014;32:912-918.
[PubMed]
https://doi.org/10.1200/JCO.2013.53.2069
13.
Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA: Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 2003;27:1346-1356.
[PubMed]
https://doi.org/10.1097/00000478-200310000-00007
14.
Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rüdiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M: Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008;111:109-111.
[PubMed]
https://doi.org/10.1182/blood-2007-03-078725
15.
Jackson C, Sirohi B, Cunningham D, Horwich A, Thomas K, Wotherspoon A: Lymphocyte-predominant Hodgkin lymphoma - clinical features and treatment outcomes from a 30-year experience. Ann Oncol 2010;21:2061-2068.
[PubMed]
https://doi.org/10.1093/annonc/mdq063
16.
Karuturi M, Hosing C, Fanale M, Medeiros LJ, Alousi AM, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson BS, Champlin R, Anderlini P, Popat U: High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma. Biol Blood Marrow Transplant 2013;19:991-994.
[PubMed]
https://doi.org/10.1016/j.bbmt.2013.03.008
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.